Monsanto to sales and distribution facilities in 51 countries. In 2005, it finalized the purchase of Seminis Inc, a leading global vegetable and fruit seed company, for $1.4 billion. This made it the world's largest conventional seed company. In 1999 Monsanto sold off NutraSweet Co. In December of the same year, Monsanto agreed to merge with Pharmacia & Upjohn, in a deal valuing the transaction at $27 billion. The agricultural division became a wholly owned subsidiary of the "new" Pharmacia; Monsanto's medical research division, which included products such as Celebrex. In 2000: Pharmacia spun off its agro-biotech subsidiary into a new
Monsanto Roundup to generic producers. Monsanto overhauled its internal controls. Two of their top CPAs were suspended and Monsanto was required to hire, at their expense, an independent ethics/compliance consultant for two years. A review of glyphosate's carcinogenic potential by four independent expert panels, with a comparison to the IARC assessment, was published in September 2016. Using emails released in August 2017 by plaintiffs' lawyers who are suing Monsanto, "Bloomberg Business Week" reported that "Monsanto scientists were heavily involved in organizing, reviewing, and editing drafts submitted by the outside experts." A Monsanto spokesperson responded that Monsanto had provided only non-substantive cosmetic